- Home
- GNLX vs AGEN Comparison
GNLX vs AGEN Comparison
Compare GNLX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- AGEN
- Stock Information
- Founded
- GNLX 2001
- AGEN 1994
- Country
- GNLX United States
- AGEN United States
- Employees
- GNLX N/A
- AGEN N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- AGEN Health Care
- Exchange
- GNLX Nasdaq
- AGEN Nasdaq
- Market Cap
- GNLX 94.0M
- AGEN 105.3M
- IPO Year
- GNLX 2023
- AGEN 2000
- Fundamental
- Price
- GNLX $2.45
- AGEN $4.13
- Analyst Decision
- GNLX Strong Buy
- AGEN Buy
- Analyst Count
- GNLX 4
- AGEN 4
- Target Price
- GNLX $17.75
- AGEN $8.33
- AVG Volume (30 Days)
- GNLX 159.0K
- AGEN 824.8K
- Earning Date
- GNLX 05-06-2025
- AGEN 05-12-2025
- Dividend Yield
- GNLX N/A
- AGEN N/A
- EPS Growth
- GNLX N/A
- AGEN N/A
- EPS
- GNLX N/A
- AGEN N/A
- Revenue
- GNLX N/A
- AGEN $99,524,000.00
- Revenue This Year
- GNLX N/A
- AGEN $14.49
- Revenue Next Year
- GNLX N/A
- AGEN N/A
- P/E Ratio
- GNLX N/A
- AGEN N/A
- Revenue Growth
- GNLX N/A
- AGEN N/A
- 52 Week Low
- GNLX $1.60
- AGEN $1.38
- 52 Week High
- GNLX $5.89
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- GNLX 44.96
- AGEN 65.54
- Support Level
- GNLX $2.42
- AGEN $2.95
- Resistance Level
- GNLX $2.78
- AGEN $3.90
- Average True Range (ATR)
- GNLX 0.21
- AGEN 0.38
- MACD
- GNLX 0.00
- AGEN -0.02
- Stochastic Oscillator
- GNLX 28.30
- AGEN 95.16
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).